Advanced Search Results

1704 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
MYC and MAPK3 v-myc avian myelocytomatosis viral oncogene homolog mitogen-activated protein kinase 3
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by FGFR in disease
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Cellular Senescence
  • ERKs are inactivated
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • Senescence-Associated Secretory Phenotype (SASP)
  • ERK1 activation
  • Signaling by VEGF
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Antiviral mechanism by IFN-stimulated genes
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Growth hormone receptor signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RNA Polymerase I Promoter Clearance
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • RNA Polymerase I Transcription
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • RNA Polymerase I Promoter Opening
  • Nuclear Events (kinase and transcription factor activation)
  • Sulindac
  • Arsenic trioxide
  • Purvalanol
  • 5-iodotubercidin
MYC and MAPK7 v-myc avian myelocytomatosis viral oncogene homolog mitogen-activated protein kinase 7
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by GPCR
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • ERKs are inactivated
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Innate Immune System
  • Signalling to ERK5
  • ERKs are inactivated
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • Senescence-Associated Secretory Phenotype (SASP)
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • ERK/MAPK targets
  • Toll Like Receptor 4 (TLR4) Cascade
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Nuclear Events (kinase and transcription factor activation)
MYC and MAPK8 v-myc avian myelocytomatosis viral oncogene homolog mitogen-activated protein kinase 8
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • Activation of BH3-only proteins
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activation of BMF and translocation to mitochondria
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • Programmed Cell Death
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Intrinsic Pathway for Apoptosis
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • Signalling by NGF
  • Cell death signalling via NRAGE, NRIF and NADE
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • DSCAM interactions
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • Activation of BIM and translocation to mitochondria
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • NRAGE signals death through JNK
  • Fc epsilon receptor (FCERI) signaling
  • MAPK targets/ Nuclear events mediated by MAP kinases
MYC and PSMC3 v-myc avian myelocytomatosis viral oncogene homolog proteasome (prosome, macropain) 26S subunit, ATPase, 3
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • Hh ligand biogenesis disease
  • T41 mutants of beta-catenin aren't phosphorylated
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • Stabilization of p53
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • DNA Replication Pre-Initiation
  • S45 mutants of beta-catenin aren't phosphorylated
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • Autodegradation of the E3 ubiquitin ligase COP1
  • AMER1 mutants destabilize the destruction complex
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • PCP/CE pathway
  • Adaptive Immune System
  • CDK-mediated phosphorylation and removal of Cdc6
  • Hedgehog ligand biogenesis
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Separation of Sister Chromatids
  • HIV Infection
  • Ubiquitin-dependent degradation of Cyclin D
  • APC truncation mutants have impaired AXIN binding
  • Assembly of the pre-replicative complex
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • p53-Dependent G1 DNA Damage Response
  • S37 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • p53-Independent DNA Damage Response
  • p53-Independent G1/S DNA damage checkpoint
  • G1/S DNA Damage Checkpoints
  • Vpu mediated degradation of CD4
  • Synthesis of DNA
  • M/G1 Transition
  • Ubiquitin-dependent degradation of Cyclin D1
  • TCF dependent signaling in response to WNT
  • SCF-beta-TrCP mediated degradation of Emi1
  • degradation of AXIN
  • Signaling by Hedgehog
  • Regulation of mitotic cell cycle
  • Degradation of GLI1 by the proteasome
  • degradation of DVL
  • Cell Cycle Checkpoints
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Regulation of Apoptosis
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Vif-mediated degradation of APOBEC3G
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • p53-Dependent G1/S DNA damage checkpoint
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • APC/C:Cdc20 mediated degradation of Securin
  • AUF1 (hnRNP D0) destabilizes mRNA
  • CDK-mediated phosphorylation and removal of Cdc6
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • truncations of AMER1 destabilize the destruction complex
  • Processing-defective Hh variants abrogate ligand secretion
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • AXIN missense mutants destabilize the destruction complex
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic Metaphase and Anaphase
  • Regulation of ornithine decarboxylase (ODC)
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Orc1 removal from chromatin
  • Mitotic Anaphase
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • Metabolism of amino acids and derivatives
  • Hedgehog 'on' state
  • Programmed Cell Death
  • Class I MHC mediated antigen processing & presentation
  • Regulation of DNA replication
  • Cell Cycle, Mitotic
  • beta-catenin independent WNT signaling
  • Orc1 removal from chromatin
  • Activation of NF-kappaB in B cells
  • Asymmetric localization of PCP proteins
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Antigen processing-Cross presentation
  • CDT1 association with the CDC6:ORC:origin complex
  • ER-Phagosome pathway
MYC and FBXW8 v-myc avian myelocytomatosis viral oncogene homolog F-box and WD repeat domain containing 8
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Class I MHC mediated antigen processing & presentation
  • Adaptive Immune System
MYC and RAF1 v-myc avian myelocytomatosis viral oncogene homolog Raf-1 proto-oncogene, serine/threonine kinase
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • MEK activation
  • FCERI mediated MAPK activation
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Rap1 signalling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • SOS-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • GP1b-IX-V activation signalling
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Adaptive Immune System
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • Ion channel transport
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • Stimuli-sensing channels
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Post NMDA receptor activation events
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Sorafenib
  • Regorafenib
  • Dabrafenib
MYC and RELA v-myc avian myelocytomatosis viral oncogene homolog v-rel avian reticuloendotheliosis viral oncogene homolog A
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Downstream signaling events of B Cell Receptor (BCR)
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activated TLR4 signalling
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TCR signaling
  • Signaling by Interleukins
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Activation of NF-kappaB in B cells
  • Interleukin-1 processing
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
MYC and FBXW7 v-myc avian myelocytomatosis viral oncogene homolog F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
  • Protein folding
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Chaperonin-mediated protein folding
  • Association of TriC/CCT with target proteins during biosynthesis
  • Class I MHC mediated antigen processing & presentation
  • Adaptive Immune System
SMAD4 and NRAS SMAD family member 4 neuroblastoma RAS viral (v-ras) oncogene homolog
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by BMP
  • Transcriptional regulation of pluripotent stem cells
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Signalling to RAS
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Adaptive Immune System
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • Activation of RAS in B cells
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Constitutive Signaling by EGFRvIII
ERBB2 and TGFA erb-b2 receptor tyrosine kinase 2 transforming growth factor, alpha
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
CAV1 and ERBB2 caveolin 1, caveolae protein, 22kDa erb-b2 receptor tyrosine kinase 2
  • Metabolism of lipids and lipoproteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Lipid digestion, mobilization, and transport
  • Signaling by Wnt
  • Basigin interactions
  • VEGFA-VEGFR2 Pathway
  • Cell surface interactions at the vascular wall
  • eNOS activation
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Metabolism of nitric oxide
  • Signaling by VEGF
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • NOSTRIN mediated eNOS trafficking
  • VEGFR2 mediated vascular permeability
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
ERBB2 and HDAC6 erb-b2 receptor tyrosine kinase 2 histone deacetylase 6
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • HSF1 activation
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Organelle biogenesis and maintenance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Assembly of the primary cilium
  • Cellular response to heat stress
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
ERBB2 and BCAR3 erb-b2 receptor tyrosine kinase 2 breast cancer anti-estrogen resistance 3
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
MDM2 and RB1 MDM2 proto-oncogene, E3 ubiquitin protein ligase retinoblastoma 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Stabilization of p53
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • PIP3 activates AKT signaling
  • Oncogene Induced Senescence
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Signalling by NGF
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Trafficking of AMPA receptors
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • Oxidative Stress Induced Senescence
  • Cell Cycle Checkpoints
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • E2F mediated regulation of DNA replication
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • Mitotic Prophase
  • Cellular Senescence
  • G1 Phase
  • Regulation of DNA replication
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Orc1 removal from chromatin
  • S Phase
  • Cyclin E associated events during G1/S transition
  • Cell Cycle, Mitotic
  • M Phase
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • G1/S Transition
  • Removal of licensing factors from origins
  • Cyclin A:Cdk2-associated events at S phase entry
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Condensation of Prophase Chromosomes
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
AR and PTEN androgen receptor phosphatase and tensin homolog
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Synthesis of PIPs at the plasma membrane
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Synthesis of IP3 and IP4 in the cytosol
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Phospholipid metabolism
  • PI Metabolism
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Negative regulation of the PI3K/AKT network
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Inositol phosphate metabolism
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • TCR signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
AR and EGFR androgen receptor epidermal growth factor receptor
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and MET epidermal growth factor receptor MET proto-oncogene, receptor tyrosine kinase
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Axon guidance
  • Semaphorin interactions
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D in semaphorin signaling
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • K-252a
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline
  • 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Cabozantinib
ABL1 and RB1 ABL proto-oncogene 1, non-receptor tyrosine kinase retinoblastoma 1
  • Role of Abl in Robo-Slit signaling
  • CDO in myogenesis
  • Axon guidance
  • Myogenesis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Signaling by Robo receptor
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • E2F mediated regulation of DNA replication
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • Mitotic Prophase
  • Cellular Senescence
  • G1 Phase
  • Regulation of DNA replication
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Orc1 removal from chromatin
  • S Phase
  • Cyclin E associated events during G1/S transition
  • Cell Cycle, Mitotic
  • M Phase
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • G1/S Transition
  • Removal of licensing factors from origins
  • Cyclin A:Cdk2-associated events at S phase entry
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Condensation of Prophase Chromosomes
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Adenosine triphosphate
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • MYRISTIC ACID
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
EGFR and TGFA epidermal growth factor receptor transforming growth factor, alpha
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
PTEN and STK11 phosphatase and tensin homolog serine/threonine kinase 11
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Synthesis of PIPs at the plasma membrane
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Synthesis of IP3 and IP4 in the cytosol
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Phospholipid metabolism
  • PI Metabolism
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Negative regulation of the PI3K/AKT network
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Inositol phosphate metabolism
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • TCR signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Insulin receptor signalling cascade
  • Integration of energy metabolism
  • IRS-mediated signalling
  • Regulation of AMPK activity via LKB1
  • mTOR signalling
  • IRS-related events
  • mTOR signalling
  • IGF1R signaling cascade
  • IRS-related events triggered by IGF1R
  • IRS-mediated signalling
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • AMPK inhibits chREBP transcriptional activation activity
  • PKB-mediated events
  • PI3K Cascade
  • PKB-mediated events
  • PI3K Cascade
  • Signaling by Insulin receptor
Page 3 out of 86 pages